双極性障害治療の世界市場レポート 2024年

双極性障害の有病率の上昇は、双極性障害治療市場の成長を促進すると予想されます。双極性障害は、不規則な睡眠パターン、意欲の低下、日常活動への興味の喪失など、障害の原因となる気分の変動や関連する症状によって特徴付けられ、人口の増加や高齢化によって負担が増大しています。このような人口動態の変化が、双極性障害治療に対する需要の増加に寄与しています。2021年、Depression and Bipolar Support Allianceは、米国人口の2.6%に相当する約570万人の成人米国人が双極性障害に罹患していると報告しました。双極性障害の発症は一般的に中央値で25歳であり、双極性障害患者の3分の2以上は、少なくとも1人の親族が同様の罹患者です。その結果、双極性障害の有病率の上昇が双極性障害治療市場の成長を促進する主要因となっています。

2023年の双極性障害治療市場で最大の地域は北米でした。欧州は予測期間中に最も急成長する地域と予想されます。双極性障害治療市場レポートの対象地域は、アジア太平洋、西欧、中東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 双極性障害治療市場の特徴

第3章 双極性障害治療市場の動向と戦略

第4章 双極性障害治療市場-マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界の双極性障害治療市場規模と成長

• 世界の双極性障害治療市場の促進要因と抑制要因
  • 市場の促進要因
  • 市場の抑制要因
• 世界の双極性障害治療市場規模実績と成長、2018～2023年
• 世界の双極性障害治療市場規模と成長予測、2023～2028年、2033年

第6章 双極性障害治療市場セグメンテーション

• 世界の双極性障害治療市場、薬剤クラス別セグメンテーション、実績および予測、2018～2023年、2023～2028年、2033年
• 気分安定剤
• 抗精神病薬
• 抗うつ薬
• その他の薬物
• 世界の双極性障害治療市場、メカニズム別セグメンテーション、実績および予測、2018～2023年、2023～2028年、2033年
• 選択的セロトニン再取り込み阻害剤
• セロトニン-ノルアドレナリン再取り込み阻害剤
• 三環系抗うつ薬
• モノアミンオキシダーゼ阻害剤
• ベンゾジアゼピン系
• ベータブロッカー
• その他の機構
• 世界の双極性障害治療市場、流通チャネル別セグメンテーション、実績および予測、2018～2023年、2023～2028年、2033年
• 病院薬局
• 小売薬局
• オンライン薬局

第7章 双極性障害治療市場の地域および国分析

• 世界の双極性障害治療市場、地域別、実績および予測、2018～2023年、2023～2028年、2033年
• 世界の双極性障害治療市場、国別、実績および予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋の双極性障害治療市場

第9章 中国の双極性障害治療市場

第10章 インドの双極性障害治療市場

第11章 日本の双極性障害治療市場

第12章 オーストラリアの双極性障害治療市場

第13章 インドネシアの双極性障害治療市場

第14章 韓国の双極性障害治療市場

第15章 西欧の双極性障害治療市場

第16章 英国の双極性障害治療市場

第17章 ドイツの双極性障害治療市場

第18章 フランスの双極性障害治療市場

第19章 イタリアの双極性障害治療市場

第20章 スペインの双極性障害治療市場

第21章 東欧の双極性障害治療市場

第22章 ロシアの双極性障害治療市場

第23章 北米の双極性障害治療市場

第24章 米国の双極性障害治療市場

第25章 カナダの双極性障害治療市場

第26章 南米の双極性障害治療市場

第27章 ブラジルの双極性障害治療市場

第28章 中東の双極性障害治療市場

第29章 アフリカの双極性障害治療市場

第30章 双極性障害治療市場の競合情勢と企業プロファイル

• 双極性障害治療市場の競合情勢
• 双極性障害治療市場の企業プロファイル
  • AbbVie Inc.
  • Pfizer Inc.
  • Astellas Pharma Inc
  • AstraZeneca PLC
  • Bristol-Myers Squibb

第31章 世界の双極性障害治療市場の競合ベンチマーキング

第32章 世界の双極性障害治療市場競合ダッシュボード

第33章 双極性障害治療市場における主要な合併と買収

第34章 双極性障害治療市場の将来展望と可能性分析

第35章 付録

“Bipolar Disorder Therapeutics Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on bipolar disorder therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for bipolar disorder therapeutics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The bipolar disorder therapeutics market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Drug Class: Mood Stabilizers; Antipsychotic Drugs; Antidepressant Drugs; Other Drugs
• 2) By Mechanism: Selective Serotonin Reuptake Inhibitors; Serotonin-norepinephrine Reuptake Inhibitors; Tricyclic Antidepressants; Monoamine Oxidase Inhibitors; Benzodiazepines; Beta-Blockers; Other Mechanisms
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Companies Mentioned: AbbVie Inc.; Pfizer Inc.; Astellas Pharma Inc; AstraZeneca PLC; Bristol-Myers Squibb
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Bipolar disorder therapeutics consist of medications such as mood stabilizers, antidepressants, antipsychotics, and psychological counseling aimed at controlling symptoms associated with bipolar disorders. These therapeutics play a crucial role in the treatment and management of bipolar disorders.

The primary categories of drugs within bipolar disorder therapeutics include mood stabilizers, antipsychotic drugs, antidepressant drugs, and other medications. Mood stabilizers constitute a class of drugs specifically designed for the management and treatment of bipolar disorders. Various mechanisms are employed, including selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors, benzodiazepines, beta-blockers, and others. These drugs are commonly available through hospital pharmacies, retail pharmacies, and online pharmacies.

The bipolar disorder therapeutics market research report is one of a series of new reports from The Business Research Company that provides bipolar disorder therapeutics market statistics, including bipolar disorder therapeutics industry global market size, regional shares, competitors with a bipolar disorder therapeutics market share, detailed bipolar disorder therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the bipolar disorder therapeutics industry. This bipolar disorder therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The bipolar disorder therapeutics market size has grown strongly in recent years. It will grow from $7.09 in 2023 to $7.53 in 2024 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period of bipolar disorder therapeutics can be attributed to factors such as increased investment in medical research and development, a rise in healthcare expenditure, an increase in the prevalence of mental health disorders, and a growing emphasis on patient advocacy.

The bipolar disorder therapeutics market size is expected to see strong growth in the next few years. It will grow to $9.46 in 2028 at a compound annual growth rate (CAGR) of 5.9%. The forecasted growth in bipolar disorder therapeutics can be attributed to factors such as the increasing prevalence of bipolar disorder, government initiatives, the expansion of healthcare infrastructure, and the growing adoption of a sedentary lifestyle. Major trends in the forecast period include personalized treatment approaches, integration of digital health solutions, the development of innovative medications, preventive interventions, and the use of neuroimaging and biomarkers for diagnosis and treatment monitoring.

The escalating prevalence of bipolar disorder is anticipated to drive the growth of the bipolar disorder therapeutics market. Characterized by disabling mood swings and associated symptoms such as irregular sleep patterns, low motivation, and a loss of interest in daily activities, bipolar disorder poses a growing burden due to population growth and aging. This demographic shift is contributing to an increased demand for bipolar disorder therapeutics. In 2021, the Depression and Bipolar Support Alliance reported that approximately 5.7 million adult Americans, constituting 2.6% of the U.S. population, were affected by bipolar disorder. The onset of bipolar disorder typically occurs at a median age of 25, with more than two-thirds of individuals with the disorder having at least one relative similarly affected. Consequently, the rising prevalence of bipolar disorder is a key driver propelling the growth of the bipolar disorder therapeutics market.

The growing demand for psychological counseling is expected to significantly contribute to the expansion of the bipolar disorder therapeutics market. Psychological counseling, a form of therapy aimed at improving mental health and enhancing overall quality of life, plays a crucial role in managing symptoms of bipolar disorder. Psychotherapy helps individuals identify triggers for bipolar episodes and equips them with coping mechanisms for stressors. According to The Centers for Disease Control and Prevention (CDC), from 2019 to 2021, there was an increase in the percentages of both men and women aged 18-44 in the U.S. who received any mental health treatment in the past 12 months. The surge in demand for psychological counseling underscores a critical aspect of bipolar disorder therapeutics, driving the market forward.

A notable trend in the bipolar disorder therapeutics market is the emergence of strategic partnerships among major companies in the sector. Companies operating in the bipolar disorder therapeutics space are actively seeking partnerships to strengthen their positions and enhance their capabilities. For example, in October 2021, Mindpax Inc., a Germany-based digital technology company in the bipolar disorder therapeutics market, partnered with Eversana Life Science Services LLC, a U.S.-based life sciences company. This collaboration aims to develop remote clinical assessments and targeted digital therapy to improve patient outcomes and offer personalized therapeutic interventions for individuals with bipolar disorder. Another significant partnership occurred in November 2020, with Biogen, a U.S.-based biotechnology company, joining forces with Sage Therapeutics, a company specializing in novel therapies for bipolar disorder and other psychiatric diseases. This partnership focuses on the commercialization of zuranolone (SAGE-217) for postpartum depression, major depressive disorder, and other psychiatric conditions, showcasing the trend of strategic collaborations in the bipolar disorder therapeutics market.

Leading companies in the Bipolar Disorder Therapeutics and related market are actively engaged in the development of new treatments specifically targeting depressive episodes associated with bipolar I or II disorder. Bipolar depression represents the most prevalent and severe clinical manifestation among bipolar disorders, often associated with poorer prognosis, longer duration, and increased recurrence compared to manic/hypomanic episodes. An illustrative example is Intra-Cellular Therapies, Inc. (ITCI), a U.S.-based biopharmaceutical company. In December 2021, ITCI announced the U.S. FDA approval for 'CAPLYTA,' a medication designed for the treatment of depressive episodes linked to bipolar I or II disorder in adults. CAPLYTA is approved for use both as monotherapy and as adjunctive therapy with lithium or valproate, exemplifying the industry's commitment to addressing the critical and prevalent aspects of bipolar disorder therapeutics.

In June 2023, Brain Therapeutics, a Greece-based central nervous system specialty company, made a strategic move by acquiring the prescription drug brand Lazap (olanzapine) from the Greek pharmaceutical company Lyofin Ltd., the terms of which were undisclosed. This acquisition, facilitated by Brain Therapeutics, aims to broaden Neuraxpharm Group's therapeutic product portfolio in Greece and Europe. The agreement positions Neuraxpharm Group to leverage its expertise in the central nervous system (CNS) field, ensuring that Lazap reaches a wider audience. Lyofin Ltd., the Greek pharmaceutical company, is a key player in this collaboration, contributing to the expansion of Neuraxpharm Group's offerings in the CNS therapeutic domain. This strategic move reflects the industry's dedication to meeting healthcare demands by enhancing its product portfolio and geographical reach.

Major companies operating in the bipolar disorder therapeutics market include AbbVie Inc., Pfizer Inc., Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb, GlaxoSmithKline PLC, Januaryssen Pharmaceuticals, Novartis AG, Otsuka Pharmaceutical Co. Ltd., Validus Pharmaceuticals, Eli Lilly and Company, Gedeon Richter PLC., Sumitomo Pharma Co. Ltd., H. Lundbeck A/S, Janssen Pharmaceuticals, Sanofi S.A., Lundbeck A/S, Allergan PLC, Takeda Pharmaceutical Company Limited, Sunovion Pharmaceuticals Inc., Alkermes PLC, Mylan N.V., Teva Pharmaceutical Industries Ltd., Johnson & Johnson, Celon Pharma SA, NeuroRx Inc., IntraCellular Therapies Inc., Sumitomo Pharma Co. Ltd., Vanda Pharmaceuticals Inc., Sage Therapeutics Inc.

North America was the largest region in the bipolar disorder therapeutics market in 2023. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the bipolar disorder therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the bipolar disorder therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The bipolar disorder therapeutics market includes revenues earned by entities by family-focused therapy, interpersonal and social rhythm therapy, cognitive behavioral therapy and dialectical behavior therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Bipolar Disorder Therapeutics Market Characteristics

3. Bipolar Disorder Therapeutics Market Trends And Strategies

4. Bipolar Disorder Therapeutics Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Bipolar Disorder Therapeutics Market Size and Growth

• 5.1. Global Bipolar Disorder Therapeutics Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Bipolar Disorder Therapeutics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Bipolar Disorder Therapeutics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Bipolar Disorder Therapeutics Market Segmentation

• 6.1. Global Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Mood Stabilizers
• Antipsychotic Drugs
• Antidepressant Drugs
• Other Drugs
• 6.2. Global Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Selective Serotonin Reuptake Inhibitors
• Serotonin-norepinephrine Reuptake Inhibitors
• Tricyclic Antidepressants
• Monoamine Oxidase Inhibitors
• Benzodiazepines
• Beta-Blockers
• Other Mechanisms
• 6.3. Global Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

7. Bipolar Disorder Therapeutics Market Regional And Country Analysis

• 7.1. Global Bipolar Disorder Therapeutics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Bipolar Disorder Therapeutics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Bipolar Disorder Therapeutics Market

• 8.1. Asia-Pacific Bipolar Disorder Therapeutics Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Bipolar Disorder Therapeutics Market

• 9.1. China Bipolar Disorder Therapeutics Market Overview
• 9.2. China Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Bipolar Disorder Therapeutics Market

• 10.1. India Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Bipolar Disorder Therapeutics Market

• 11.1. Japan Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.2. Japan Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Bipolar Disorder Therapeutics Market

• 12.1. Australia Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Bipolar Disorder Therapeutics Market

• 13.1. Indonesia Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Bipolar Disorder Therapeutics Market

• 14.1. South Korea Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.2. South Korea Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Bipolar Disorder Therapeutics Market

• 15.1. Western Europe Bipolar Disorder Therapeutics Market Overview
• 15.2. Western Europe Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Bipolar Disorder Therapeutics Market

• 16.1. UK Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Bipolar Disorder Therapeutics Market

• 17.1. Germany Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Bipolar Disorder Therapeutics Market

• 18.5. France Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.6. France Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.7. France Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Bipolar Disorder Therapeutics Market

• 19.9. Italy Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.10. Italy Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.11. Italy Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Bipolar Disorder Therapeutics Market

• 20.13. Spain Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.14. Spain Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.15. Spain Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Bipolar Disorder Therapeutics Market

• 21.1. Eastern Europe Bipolar Disorder Therapeutics Market Overview
• 21.2. Eastern Europe Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Bipolar Disorder Therapeutics Market

• 22.1. Russia Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Bipolar Disorder Therapeutics Market

• 23.1. North America Bipolar Disorder Therapeutics Market Overview
• 23.2. North America Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Bipolar Disorder Therapeutics Market

• 24.1. USA Bipolar Disorder Therapeutics Market Overview
• 24.2. USA Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Bipolar Disorder Therapeutics Market

• 25.1. Canada Bipolar Disorder Therapeutics Market Overview
• 25.2. Canada Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Bipolar Disorder Therapeutics Market

• 26.1. South America Bipolar Disorder Therapeutics Market Overview
• 26.2. South America Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Bipolar Disorder Therapeutics Market

• 27.1. Brazil Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Bipolar Disorder Therapeutics Market

• 28.1. Middle East Bipolar Disorder Therapeutics Market Overview
• 28.2. Middle East Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Bipolar Disorder Therapeutics Market

• 29.1. Africa Bipolar Disorder Therapeutics Market Overview
• 29.2. Africa Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Bipolar Disorder Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Bipolar Disorder Therapeutics Market Competitive Landscape
• 30.2. Bipolar Disorder Therapeutics Market Company Profiles
  • 30.2.1. AbbVie Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Pfizer Inc.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Astellas Pharma Inc
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. AstraZeneca PLC
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Bristol-Myers Squibb
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Global Bipolar Disorder Therapeutics Market Competitive Benchmarking

32. Global Bipolar Disorder Therapeutics Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Bipolar Disorder Therapeutics Market

34. Bipolar Disorder Therapeutics Market Future Outlook and Potential Analysis

• 34.1 Bipolar Disorder Therapeutics Market In 2028 - Countries Offering Most New Opportunities
• 34.2 Bipolar Disorder Therapeutics Market In 2028 - Segments Offering Most New Opportunities
• 34.3 Bipolar Disorder Therapeutics Market In 2028 - Growth Strategies
• 34.3.1 Market Trend Based Strategies
• 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer